Want to see TSE:GUD full AI Analyst Report?
Knight Therapeutics (GUD) Ratios
Knight Therapeutics Ratios
TSE:GUD's free cash flow for Q2 2026 was $26.97M. For the 2026 fiscal year, TSE:GUD's free cash flow was decreased by $-621.00K and operating cash flow was $27.59M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.39 | 3.57 | 3.20 | 2.80 | 2.92 |
| Quick Ratio | 1.57 | 2.64 | 2.40 | 2.14 | 2.23 |
| Cash Ratio | 0.46 | 0.72 | 0.52 | 0.51 | 0.82 |
| Solvency Ratio | 0.18 | 0.34 | 0.17 | 0.14 | 0.42 |
| Operating Cash Flow Ratio | 0.43 | 0.33 | 0.32 | 0.29 | 0.42 |
| Short-Term Operating Cash Flow Coverage | 4.20 | 2.07 | 2.01 | 2.29 | 1.67 |
| Net Current Asset Value | $ 115.81M | $ 228.12M | $ 166.49M | $ 166.64M | $ 157.45M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.05 | 0.07 | 0.07 | 0.04 |
| Debt-to-Equity Ratio | 0.10 | 0.06 | 0.09 | 0.09 | 0.05 |
| Debt-to-Capital Ratio | 0.09 | 0.06 | 0.08 | 0.09 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.06 | 0.03 | 0.06 | 0.06 | 0.01 |
| Financial Leverage Ratio | 1.36 | 1.21 | 1.27 | 1.28 | 1.18 |
| Debt Service Coverage Ratio | 2.05 | 2.50 | 1.52 | 1.62 | 1.70 |
| Interest Coverage Ratio | -0.21 | 0.80 | -0.23 | -0.36 | -1.47 |
| Debt to Market Cap | 0.11 | 0.08 | 0.11 | 0.12 | 0.05 |
| Interest Debt Per Share | 0.89 | 0.58 | 0.76 | 0.73 | 0.36 |
| Net Debt to EBITDA | 0.03 | -0.48 | 0.25 | 0.24 | -1.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 33.49% | 46.97% | 46.51% | 47.03% | 47.40% |
| EBIT Margin | -0.49% | 3.04% | -2.89% | -12.73% | 4.23% |
| EBITDA Margin | 12.08% | 17.34% | 12.46% | 8.60% | 17.49% |
| Operating Profit Margin | -0.49% | 1.99% | -0.88% | -0.82% | -2.19% |
| Pretax Profit Margin | -1.49% | 0.55% | -6.70% | -14.97% | 2.75% |
| Net Profit Margin | -1.19% | 1.17% | -5.13% | -10.18% | 6.44% |
| Continuous Operations Profit Margin | -1.19% | 1.17% | -5.13% | -10.18% | 6.44% |
| Net Income Per EBT | 80.19% | 211.11% | 76.56% | 68.00% | 234.30% |
| EBT Per EBIT | 304.50% | 27.74% | 760.83% | 1829.38% | -125.70% |
| Return on Assets (ROA) | -0.51% | 0.45% | -1.78% | -2.83% | 1.58% |
| Return on Equity (ROE) | -0.70% | 0.54% | -2.25% | -3.62% | 1.86% |
| Return on Capital Employed (ROCE) | -0.25% | 0.87% | -0.35% | -0.26% | -0.60% |
| Return on Invested Capital (ROIC) | -0.20% | 0.85% | -0.26% | -0.17% | -0.58% |
| Return on Tangible Assets | -0.93% | 0.73% | -2.92% | -4.72% | 2.77% |
| Earnings Yield | -0.89% | 0.80% | -3.02% | -5.02% | 2.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.26 | 3.27 | 3.34 | 2.70 | 3.61 |
| Payables Turnover | 2.48 | 2.51 | 2.06 | 1.47 | 1.96 |
| Inventory Turnover | 2.20 | 1.92 | 1.91 | 1.68 | 1.77 |
| Fixed Asset Turnover | 20.53 | 18.54 | 18.38 | 12.97 | 8.13 |
| Asset Turnover | 0.43 | 0.39 | 0.35 | 0.28 | 0.25 |
| Working Capital Turnover Ratio | 1.75 | 1.38 | 1.30 | 1.29 | 0.76 |
| Cash Conversion Cycle | 130.39 | 156.75 | 122.69 | 103.13 | 121.26 |
| Days of Sales Outstanding | 112.10 | 111.61 | 109.24 | 134.98 | 101.06 |
| Days of Inventory Outstanding | 165.67 | 190.38 | 190.94 | 217.09 | 206.34 |
| Days of Payables Outstanding | 147.38 | 145.23 | 177.49 | 248.95 | 186.14 |
| Operating Cycle | 277.77 | 301.98 | 300.19 | 352.08 | 307.40 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.71 | 0.36 | 0.33 | 0.35 | 0.36 |
| Free Cash Flow Per Share | 0.69 | 0.05 | 0.24 | 0.13 | -1.44 |
| Dividend Paid and CapEx Coverage Ratio | 36.85 | 1.15 | 3.61 | 1.57 | 0.20 |
| Capital Expenditure Coverage Ratio | 36.85 | 1.15 | 3.61 | 1.57 | 0.20 |
| Operating Cash Flow Coverage Ratio | 0.90 | 0.73 | 0.52 | 0.52 | 1.09 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.10 | 0.11 | 0.14 | 0.18 |
| Free Cash Flow Yield | 11.35% | 0.89% | 4.66% | 2.46% | -27.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -112.04 | 124.77 | -33.13 | -19.91 | 42.09 |
| Price-to-Sales (P/S) Ratio | 1.34 | 1.45 | 1.70 | 2.03 | 2.71 |
| Price-to-Book (P/B) Ratio | 0.79 | 0.68 | 0.75 | 0.72 | 0.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 8.81 | 112.22 | 21.47 | 40.58 | -3.67 |
| Price-to-Operating Cash Flow Ratio | 8.57 | 14.87 | 15.52 | 14.70 | 14.79 |
| Price-to-Earnings Growth (PEG) Ratio | 0.50 | -0.98 | 0.86 | 0.07 | -0.92 |
| Enterprise Value Multiple | 11.11 | 7.90 | 13.89 | 23.80 | 14.43 |
| Enterprise Value | 603.84M | 508.91M | 568.08M | 601.15M | 614.74M |
| EV to EBITDA | 11.11 | 7.90 | 13.89 | 23.80 | 14.43 |
| EV to Sales | 1.34 | 1.37 | 1.73 | 2.05 | 2.52 |
| EV to Free Cash Flow | 8.83 | 105.85 | 21.87 | 40.99 | -3.42 |
| EV to Operating Cash Flow | 8.59 | 14.03 | 15.81 | 14.85 | 13.78 |
| Tangible Book Value Per Share | 2.99 | 4.21 | 3.51 | 3.52 | 3.34 |
| Shareholders’ Equity Per Share | 7.71 | 7.87 | 6.95 | 7.19 | 6.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | -1.11 | 0.23 | 0.32 | -1.34 |
| Revenue Per Share | 4.52 | 3.67 | 3.05 | 2.56 | 1.96 |
| Net Income Per Share | -0.05 | 0.04 | -0.16 | -0.26 | 0.13 |
| Tax Burden | 0.80 | 2.11 | 0.77 | 0.68 | 2.34 |
| Interest Burden | 3.04 | 0.18 | 2.31 | 1.18 | 0.65 |
| Research & Development to Revenue | 0.06 | 0.06 | 0.05 | 0.05 | 0.05 |
| SG&A to Revenue | 0.28 | 0.27 | 0.11 | 0.14 | 0.15 |
| Stock-Based Compensation to Revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Income Quality | -13.08 | 8.37 | -2.13 | -1.35 | 2.85 |
Currency in CAD
